Clinical trials: High-risk Pregnancy
Tranexamic Acid Administration, Postpartum Hemorrhage
Tranexamic Acid for Reducing Blood Loss in High-Risk Cesarean Delivery
This randomized study evaluated whether prophylactic tranexamic acid (TXA) reduces perioperative blood loss in women at increased risk of postpartum hemorrhage undergoing elective cesarean delivery.
- Conditions
- Tranexamic Acid Administration, Postpartum Hemorrhage, Blood Transfusion, Perioperative Blood Loss
- Trial name
- TXA (NCT07870499)
- Testing
- Tranexamic Acid
- Where
- Turkey (Türkiye)
- Volunteers
- 84 people
- Sponsor
- Mert Yetgin
Premature Infants
Post-Discharge Growth and Development of Infants Who Received Targeted Fortification in the NICU
Extremely low birth weight (ELBW) infants are at risk for slow growth, metabolic abnormalities, and poor neurodevelopmental outcomes.
- Trial name
- NCT04190875
- Where
- United States
- Volunteers
- 120 people, healthy volunteers welcome
- Sponsor
- Baylor College of Medicine
Cervical Cancer
Use of High-Resolution Microendoscopy (HRME) in Patients With Cervical Dysplasia
The goal of this clinical research study is to compare a type of imaging called high-resolution microendoscopy (HRME) for detecting abnormal tissue in the cervix to the standard of care, which is visual inspection with acetic…
- Trial name
- NCT02420665
- Testing
- Proflavine, HRME Imaging, Phone Call
- Where
- 2 sites in United States
- Volunteers
- 50 people
- Sponsor
- M.D. Anderson Cancer Center
Bladder Cancer Stage 0, Bladder Cancer Stage I
Efficacy and Safety of Obturator Nerve Block During Transurethral Resection on Non-muscle Invasive Intermediate and High Risk Lateral Wall Bladder Tumours
In this prospective randomized controlled study, the effects of obturator nerve block (ONB) on obturator reflex, incomplete resection, perforation, tumor recurrence and progression, presence of muscle tissue in the specimen, need…
- Trial name
- NCT04885309
- Testing
- Nerve Stimulator-guided Obturator Nerve Block
- Where
- Turkey (Türkiye)
- Volunteers
- 104 people
- Sponsor
- Ankara Training and Research Hospital
Clear Cell Renal Cell Carcinoma
Neoadjuvant PD-L1 Inhibitor Plus Anlotinib for Kidney Preservation in Complex Renal Cell Carcinoma
This is a prospective, multicenter, single-arm phase II study evaluating the efficacy and safety of neoadjuvant PD-L1 inhibitor TQB2450 in combination with anlotinib in patients with locally advanced, high-complexity (RENAL score…
- Trial name
- NCT07602101
- Testing
- TQB2450 + Anlotinib
- Volunteers
- 33 people
- Sponsor
- RenJi Hospital
Renal Cell Carcinoma
High Dose IL 2 and Entinostat in RCC
This is a multicenter, randomized, open label study of high dose interleukin 2 vs high dose interleukin 2 plus entinostat in clear cell RCC patients who are candidate for high dose interleukin 2.
- Trial name
- NCT03501381
- Testing
- Entinostat, Interleukin-2
- Where
- 5 sites in United States
- Volunteers
- 46 people
- Sponsor
- Roberto Pili
Ovarian Cancer, HGSOC
Study of CryptiVax-1001 in Maintenance Setting for Advanced Serous Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Ovarian, fallopian tube, or primary peritoneal cancer, collectively referred to as ovarian cancer, remains the deadliest type of gynaecological cancer.
- Conditions
- Ovarian Cancer, HGSOC, HGS Ovarian, Fallopian Tube or Primary Peritoneal Cancer
- Trial name
- OVACT (NCT07665515)
- Testing
- CryptiVax-1001
- Where
- 10 sites in United Kingdom
- Volunteers
- 50 people
- Sponsor
- Epitopea Ltd
Gynecologic Malignant Tumor
The Study of Massively Parallel Sequencing in Early Detection for Gynecologic Malignant Tumor
As human aging, 50% of women will be faced with the threat of cancer, especially gynecological malignancies. Ovarian, cervical and endometrial cancer are three major gynecological malignancies.
- Trial name
- NCT02166515
- Where
- China
- Volunteers
- 200 people, healthy volunteers welcome
- Sponsor
- Zhiqing, Liang
Cervical Cancer Screening, Cervical Cancer
Evaluation of Three Strategies Based on Vaginal Self-sampling Kit Send to Home of Unscreened Women for Cervical Cancer
Despite the existence of an effective screening test (pap smear), cervical cancer is, every year in France, the cause of more than 3,000 new cases and 1,100 deaths.
- Trial name
- APACHE-4 (NCT03856684)
- Testing
- Self-sampling kit sent at home, Self-sampling kit sent at home + SMS reminder, Letter offering a self-sampling kit "on request"+ SMS reminder
- Where
- France
- Volunteers
- 10,400 people, healthy volunteers welcome
- Sponsor
- University Hospital, Tours
Type 2 Diabetes
Salt Intake and Antiproteinuric Effect of Paricalcitol in Type 2 Diabetes
Proteinuria is an independent risk factor for cardiovascular morbidity and mortality and for renal disease progression. More proteinuria is associated with faster progression, whereas treatments that reduce proteinuria are…
- Trial name
- PROCEED (NCT01393808)
- Testing
- Paricalcitol
- Where
- 6 sites in Italy
- Volunteers
- 112 people
- Sponsor
- Mario Negri Institute for Pharmacological Research
ASC-US, ASC-H
Phase II Study of Treatment for HPV16+ ASC-US, ASC-H and LSIL
To evaluate the safety and tolerability of the dual IM pNGVL4a Sig/E7(detox)/HSP70 DNA and single IM TA-CIN immunization regimen To evaluate the efficacy of dual IM pNGVL4a-Sig/E7(detox)/HSP70 DNA and single IM TA-CIN…
- Conditions
- ASC-US, ASC-H, LSIL
- Trial name
- PVX2 (NCT03911076)
- Testing
- PVX-2
- Where
- 6 sites in United States
- Volunteers
- 16 people
- Sponsor
- PapiVax Biotech, Inc.
Bladder Cancer
Safety and Efficacy of CG0070 Oncolytic Virus Regimen for High Grade NMIBC After BCG Failure
To study the safety and efficacy of CG0070, an oncolytic virus expression GM-CSF in high grade non muscle invasive bladder cancer patients who failed BCG therapy and refused cystectomy.
- Trial name
- BOND2 (NCT02365818)
- Testing
- CG0070
- Where
- 17 sites in United States
- Volunteers
- 66 people
- Sponsor
- CG Oncology, Inc.
Non-muscle-invasive Bladder Cancer
Artificial Intelligence Prediction Tool in Non-muscle Invasive Bladder Cancer (NMIBC)
This is a multi-center study and the aim is to develop and validate an Artificial Intelligence (AI) -based histologic analysis tool to predict responsiveness to intravesical Bacillus Calmette-Guérin (BCG) and intravesical…
- Trial name
- NCT05825950
- Where
- 2 sites in United States
- Volunteers
- 600 people
- Sponsor
- University of Texas Southwestern Medical Center
PreTerm Birth
New Tool to Predict Risk of Spontaneous Preterm Birth in Asymptomatic High-risk Women
The QUIPP tool integrates information of obstetrical history, quantitative fetal fibronectin (qfFN) and cervical length to predict the risk of sPTB in asymptomatic high-risk women.
- Trial name
- NCT03062020
- Testing
- QUIPP
- Where
- 2 sites in Spain
- Volunteers
- 258 people, healthy volunteers welcome
- Sponsor
- Hospital Clinic of Barcelona
Dysfunctional Uterine Bleeding
DMPA & High Dose Oral Progestin (MPA) Tablets in Outpatient Treatment of Acute Excessive Vaginal Bleeding
The purpose of this study is to investigate the effectiveness and acceptability of high dose MPA (20mg oral 3 times a day) for 3 days combined with an injection of DMPA 150 mg intramuscularly in the treatment of acute heavy…
- Trial name
- NCT01148420
- Testing
- Medroxyprogesterone 17-Acetate, medroxyprogesterone acetate
- Where
- United States
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- Women's Health Care Clinic, Torrance, California
Stress Urinary Incontinence
The Effect of Pelvic Floor Muscle Training With Stabilization Exercises With Various Intensity in Women With Stress Urinary Incontinence
This study will evaluate the safety, tolerability and efficacy of high- and low-intensity PFMT with stabilization exercises in women with SUI
- Trial name
- PELSTAB (NCT04340323)
- Testing
- Pelvic Floor Muscle Training (PFMT)
- Where
- Slovakia
- Volunteers
- 86 people
- Sponsor
- Pavol Jozef Safarik University
Rhabdomyolysis, Renal Failure
Myoglobin Removal by High Cut-off CVVHD
A high cut-off dialyzer (septeX) is tested for the removal of myoglobin which is not efficiently removed by standard high flux dialysis membranes.
- Trial name
- HicoRhabdo (NCT01467180)
- Testing
- septeX, HF CVVH
- Where
- Germany
- Volunteers
- 16 people
- Sponsor
- Vantive Health LLC
Urinary Tract Infection
Diagnosis of Subclinical Urinary Tract Infections Using Advanced Microbiome Survey Techniques in High Risk Trauma Patients
The purpose of this study is to see if the investigators can identify early those patients who are admitted to the hospital and have a urinary tract infection (UTI) or those patients that develop a UTI during their…
- Trial name
- NCT01834391
- Where
- United States
- Volunteers
- 129 people
- Sponsor
- Mayo Clinic
Kidney Diseases
A Trial of Tolerogenic Immunosuppression in Highly Sensitized Renal Transplant Recipients
Comparison between Campath induction and monotherapy with Tacrolimus vs Thymoglobulin induction and triple drug maintenance using Tacrolimus, mycophenolate, and steroids.
- Trial name
- NCT00407160
- Where
- United States
- Volunteers
- 21 people
- Sponsor
- The University of Texas Medical Branch, Galveston
Hydronephrosis, Infiltrating Bladder Urothelial Carcinoma Sarcomatoid Variant
Durvalumab and Tremelimumab in Treating Patients With Muscle-Invasive, High-Risk Urothelial Cancer That Cannot Be Treated With Cisplatin-Based Therapy Before Surgery
This pilot phase I trial studies the side effects of durvalumab and tremelimumab in treating patients with muscle-invasive, high-risk urothelial cancer that cannot be treated with cisplatin-based therapy before surgery.
- Conditions
- Hydronephrosis, Infiltrating Bladder Urothelial Carcinoma Sarcomatoid Variant, Infiltrating Bladder Urothelial Carcinoma, Micropapillary Variant, Infiltrating Bladder Urothelial Carcinoma, Plasmacytoid Variant
- Trial name
- NCT02812420
- Testing
- Durvalumab, Therapeutic Conventional Surgery, Tremelimumab
- Where
- United States
- Volunteers
- 54 people
- Sponsor
- M.D. Anderson Cancer Center
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.